Fertility preservation in a newly diagnosed breast cancer patient — structured SAQ (15 marks)

(a) Immediate priorities and rationale (4 marks)

One mark per point, maximum four. ^[2]

• Initiate and document the fertility preservation discussion as early as possible and refer to reproductive specialists without delay — the ASCO 2018 guideline requires this so that the widest array of options remains available; cyclophosphamide is gonadotoxic and the window before chemotherapy is short.^[2]
• Run the multidisciplinary discussion in parallel with staging, not in series — oncology, reproductive medicine, anaesthetics and psychology; the diagnosis-to-treatment interval is the key determinant of feasibility.^[1]
• Confirm ovarian reserve and timeline — AMH 2.1 ng/mL and antral follicle count 9 indicate a moderate reserve; with two and a half weeks available, conventional or random-start oocyte or embryo cryopreservation is feasible.^[1]
• Counsel on strategy by partner status and preference, and obtain storage and disposition consent — storage duration, posthumous use, and disposition must be documented.^[2]

(b) The stimulation protocol (5 marks)

One mark for the backbone, one for the letrozole dose, one for the trigger, one for the safety citation, one for stating the timing. ^[1]

• GnRH antagonist backbone with random-start — stimulation can be initiated at any cycle phase; von Wolff showed yield is not compromised by luteal start.^[1]
• Letrozole 5 mg daily co-administration with FSH throughout stimulation — the Oktay 2005 protocol, established to suppress peak oestradiol in oestrogen-receptor-positive disease while maintaining embryo yield.^[4]
• GnRH agonist trigger instead of hCG — reduces post-trigger oestrogen exposure and ovarian hyperstimulation syndrome risk in the cancer patient.^[1]
• Long-term oncological safety — the Kim, Turan and Oktay 2016 study (mean 5-year follow-up) found the hazard ratio for recurrence after letrozole-gonadotropin stimulation was 0.77 (95% CI 0.28 to 2.13), with survival not compromised.^[3]
• Timing — oocyte or embryo cryopreservation completed so that chemotherapy proceeds on the oncologist's schedule; random-start keeps the delay short.^[1]

(c) Oocyte versus embryo cryopreservation (3 marks)

One mark for oocyte advantage/trade-off, one for embryo advantage/trade-off, one for applying it to this patient. ^[1]

• Oocyte cryopreservation — the established option for a woman without a committed sperm source; 85.2 per cent survival post-warming (Cobo 2016); trade-off is lower per-cycle yield than embryo and dependence on later fertilisation.
• Embryo cryopreservation — the highest live-birth yield per cycle and the longest track record; trade-off is that it requires a sperm decision now and creates embryos whose disposition is more complex if the couple separates or one dies.
• For this patient — with a male partner of four years, embryo cryopreservation is reasonable for the highest yield; oocyte cryopreservation preserves her autonomy if the relationship status changes. A combination of both is acceptable.

(d) Role of the GnRH agonist (3 marks)

One mark for the adjunct role, one for the evidence, one for why it is not a substitute. ^[2]

• Adjunct role — ASCO states a GnRH agonist may be offered to young women with breast cancer in the hope of reducing chemotherapy-induced ovarian insufficiency, when proven methods are not feasible or as an adjunct.^[2]
• Evidence — the Lambertini 2018 individual patient-data meta-analysis of 873 patients found premature ovarian insufficiency of 14.1 per cent with GnRHa versus 30.9 per cent control (adjusted OR 0.38; 95% CI 0.26 to 0.57), and a higher post-treatment pregnancy rate (10.3 per cent versus 5.5 per cent), with no difference in disease-free or overall survival. POEMS/SWOG (Moore 2015) showed ovarian failure of 8 per cent versus 22 per cent in hormone-receptor-negative disease.^[6][5]
• Not a substitute — ASCO is explicit that a GnRH agonist must not be used in place of proven fertility preservation methods; it does not store gametes, and the live-birth benefit is less robust than for cryopreservation.^[2]